Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Parathyroid hormone (1-34) (human) in Kidney Assays
2026-10-01
Use this defined PTH stimulus to connect receptor-proximal cAMP signaling with bone remodeling, serum calcium regulation, and spatially organized kidney assembloid assays. The workflow emphasizes dose finding, fresh peptide handling, compartment-aware readouts, and clear separation between established product performance and emerging kidney-model applications.
-
ABT-263 (Navitoclax): Practical Assay Guide
2026-10-01
This guide explains how to prepare, control, and interpret ABT-263 (Navitoclax), SKU A3007, in apoptosis assays and cancer biology workflows when no directly matched paper evidence is available. It is intended for research use only and does not provide clinical dosing, diagnostic guidance, or cell-line-specific treatment conditions.
-
mRNA Vaccine Memory: Antigen vs LNP Immunity
2026-09-30
The reference study presents SAPC-LNPs, a sialic acid- and cleavable PEG-modified lipid nanoparticle designed to improve dendritic-cell delivery while limiting immune memory against the carrier. In mice, this formulation supported stronger tumor-antigen memory, weaker anti-LNP responses, reduced adverse effects, and more durable protection than a commercial comparator, although translation beyond the reported models remains uncertain.
-
FPH1 and the Next Generation of Liver Cell Models
2026-09-30
A translational perspective on how FPH1 (BRD-6125) can align hepatocyte expansion with functional maturity, improve assay design, and inform future strategies for more controllable liver cell and gene therapy platforms.
-
WAY-100635 Workflows for 5-HT1A Pain Studies
2026-09-29
WAY-100635 helps convert serotonergic correlations into causal tests across receptor binding, functional, behavioral, and imaging workflows. This guide shows how to use selective 5-HT1A blockade to interrogate cannabidiol-related pain and affect mechanisms while avoiding common solvent, timing, and interpretation errors.
-
High Yield T7 Biotin16 RNA Labeling Kit
2026-09-29
The High Yield T7 Biotin16 RNA Labeling Kit, SKU K1082, is positioned for generating biotin-labeled RNA through a T7-based workflow. Its practical value is assay preparation: it can support RNA capture, detection, or interaction studies, but it does not by itself measure m6A or establish the METTL14-SMN mechanism described in the reference study.
-
WAY-100635 in 5-HT1A Pain Research
2026-09-28
WAY-100635 provides a selective pharmacological test of 5-HT1A receptor involvement across binding, functional, behavioral, and translational imaging workflows. This guide connects receptor-level antagonism with the sensory, affective, and cognitive endpoints highlighted in contemporary inflammatory pain research.
-
Cefiderocol vs Resistant European Nonfermenters
2026-09-28
A 2020 multicountry surveillance study compared cefiderocol with established and emerging β-lactam/β-lactamase inhibitor combinations against European Pseudomonas aeruginosa and Acinetobacter spp. Cefiderocol susceptibility remained high among many meropenem- and combination-resistant isolates, while resistance-associated genetic findings underline the value of testing each isolate rather than inferring activity from another drug’s result.
-
15-PGDH Inhibition Supports Muscle Repair During Weight Loss
2026-09-27
A mouse study reports that inhibiting 15-PGDH alongside semaglutide can improve muscle stem cell activity, regenerated fiber growth, and post-injury strength without negating weight loss. The findings position 15-PGDH as a candidate target for protecting muscle quality during GLP-1 receptor agonist treatment, while leaving important questions about mechanism and human translation open.
-
Baicalein and Translational Pathway Selectivity
2026-09-26
How Baicalein’s 12-LOX research profile can support more rigorous studies of cancer biology and inflammation—and what recent neurotoxicity research teaches about preserving therapeutic context.
-
Calcitriol Workflows for Decidualization Research
2026-09-25
Use Calcitriol to test how direct vitamin D receptor activation shapes endometrial stromal-cell decidualization, with practical guidance for dose selection, sampling, and readouts. The workflow connects VDR perturbation to PRL, IGFBP1, and estrogen-pathway measurements while distinguishing study findings from suggested pilot conditions.
-
Berberrubine, Vitamin K Cycling, and Thrombosis
2026-09-25
A mouse study combined carrageenan-induced tail thrombosis, non-targeted metabolomics, coagulation measurements, and molecular docking to investigate how berberrubine affects thrombosis. The results implicate vitamin K-cycle regulation, while the separation between reduced thrombosis and unchanged bleeding time is promising but requires further validation.
-
Perospirone Inhibits Coronary Kv1.5 Channels
2026-09-24
A study in freshly isolated rabbit coronary arterial smooth muscle cells identifies voltage-gated K+ current inhibition as an off-target action of Perospirone, with pharmacological evidence implicating Kv1.5-associated channels. The findings add a vascular mechanism to its established receptor pharmacology, while leaving open whether the in vitro effect occurs at clinically relevant exposure or alters cardiovascular function in vivo.
-
MLN2238: Applied Workflows for Proteasome Stress
2026-09-24
Use MLN2238 to connect β5 proteasome inhibition with measurable proteotoxic-stress responses, from target-engagement assays to ROS/JNK/CREB signaling. This workflow pairs concentration and time-course optimization with practical controls for solubility, selectivity, and cross-model interpretation.
-
ICI 118,551 Hydrochloride: Evidence and Use
2026-09-23
ICI 118,551 hydrochloride is a research tool identified with β2-adrenoceptor antagonism; receptor selectivity should be interpreted in the context of the assay and experimental system. The cited stroke-rehabilitation study tested esculetin, not ICI 118,551, so it does not establish this product as a stroke treatment or as a neutrophil-infiltration inhibitor.